Valproic Acid Antibody (Mouse Monoclonal)

Description

Monoclonal Antibody to Valproic Acid. 5 different clones are available.

References

• Valproic acid enhances the viability of random pattern skin flaps: involvement of enhancing angiogenesis and inhibiting oxidative stress and apoptosis. Wu H, Ding J, Wang L, Lin J, Li S, Xiang G, Jiang L, Xu H, Gao W, Zhou K. Drug Des Devel Ther. 2018 Nov 16;12:3951-3960.
• Valproicacid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Nau H, Hauck RS, Ehlers K. Pharmacol Toxicol. 1991 Nov;69(5):310-21.
• Evaluation of the mood-stabilizing agent valproicacid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice. Goodwin DG, Strobl J, Mitchell SM, Zajac AM, Lindsay DS. J Parasitol. 2008 Apr;94(2):555-7.
• Valproicacid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproicacid-induced neural tube defects. Defoort EN, Kim PM, Winn LM. Mol Pharmacol. 2006 Apr;69(4):1304-10.
• Derivatization oriented strategy for enhanced detection of valproicacid and its metabolites in human plasma and detection of valproicacid induced reactive oxygen species associated protein modifications by mass spectrometry. Wu CY, Lu CY. J Chromatogr A. 2014 Dec 29;1374:14-22.
• Acute valproicacid overdose. Clinical course and pharmacokinetic disposition of valproicacid and metabolites. Dupuis RE, Lichtman SN, Pollack GM. Drug Saf. 1990 Jan-Feb;5(1):65-71.
• Effects of long-term valproic acid treatment on hematological and biochemical parameters in adolescent psychiatric inpatients: a retrospective naturalistic study. Amitai M, Sachs E, Zivony A, Remez R, Ben Baruch R, Amit BH, Kronenberg S, Apter A, Shoval G, Weizman A, Zalsman G. Int Clin Psychopharmacol. 2015 Sep;30(5):241-8.